 |
BIOX to Showcase ECG Holter and Ambulatory Blood Pressure Products at Medical Fair India 2013 |
NEW YORK / FEBRUARY 27, 2013 - VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® systems, the gold standard of ECP therapy, as well as ECG Holter and ambulatory blood pressure monitoring products, announced today that that its wholly-owned subsidiary, BIOX Instruments Co. Ltd., will exhibit at Medical Fair India 2013 from March 8-10 in Pragati Maidan, New Delhi, India.
At the event, BIOX will present its ECG Holter and ambulatory blood pressure monitoring product line which includes a lightweight, ultra-compact ECG Holter recorder, a highly accurate and reliable ambulatory blood pressure monitor with arterial pulse waveform verification, and the only FDA-cleared Combined ECG Holter and Ambulatory Blood Pressure Monitor on the market. The efficient, easy-to-use BIOX Analysis and Reporting software will also be demonstrated to interested clinicians and distributors attending the event.
In addition, BIOX, with its expertise in miniaturization and low power consumption medical devices, makes an excellent OEM partner in medical device projects. Whether repackaging an existing technology or designing and developing new products, BIOX can make a valuable contribution to any “go to market” plan.
This year's Medical Fair India is the 19th annual International Exhibition & Conference on Diagnostic, Medical Technology, Rehabilitation, Medical Equipment and Components. In previous years, this conference, which is the leading event for the Indian healthcare market, has attracted more than 322 exhibitors from 17 different countries and more than 6,700 visitors from across the globe. The exhibition will feature products and services from medical technology companies, hospital and healthcare centers, and international physician networks.
“The healthcare sector in India is one of the largest and fastest growing in the world, and Medical Fair India is a great occasion to reach out to the Indian and international medical communities. At this event, the BIOX team will have the opportunity to showcase its feature rich product line, and use the conference as a opportunity to expand our presence in India and open up new markets,” said Qiuming Shen, president of BIOX.
The BIOX exhibit will be located at Booth C31.
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
About VasoGlobal
VasoMedical Global Corp. (VasoGlobal), a wholly-owned subsidiary of VasoMedical Inc. was established to manage the operations of the Company's operating subsidiaries in China and identify and manage potential accretive acquisitions the Company may consider. Some of the operations VasoGlobal manages are the establishment and managing of sales channels, product development, marketing of innovative, low cost technologies, regulatory clearances, OEM partnerships and manufacturing. VasoGlobal is a committed team of healthcare professionals dedicated to finding partnerships that will improve and optimize healthcare delivery at lower costs. Additional information is available on the Company's website at www.vasoglobal.com.
About BIOX
BIOX Instruments Co., Ltd., a wholly owned subsidiary of VasoMedical, is based in Wuxi, Jiangsu Province, China. With long established expertise in miniaturization and low power consumption medical devices, it is a leading company in ambulatory monitoring systems consisting of ECG Holter recorders, ambulatory blood pressure monitoring (ABPM) systems as well as related analysis and reporting software. BIOX is in full compliance of revered quality and manufacturing standards such as ISO 13485, ISO 9001, US FDA cGMP as well as the Medical Device Directive of the European Union. BIOX products are FDA Cleared, CE Marked and Health Canada Listed. Furthermore, BIOX continues to provide OEM and OED services to many businesses that require effective solutions to product design and performance. Additional information is available on the Company's website at www.biox.com.cn.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
212-896-1216 / 212-896-1220
lgoldberg@kcsa.com / swolf@kcsa.com